产品名称

英文名称：Monophosphoryl Lipid A (Synthetic)

同义词

GLA 、 GLUCOPYRANOSYL LIPID A AMMONIUM 、 GLA-SE 、 MONOPHOSPHORYL LIPID A (SYNTHETIC) AMMONIUM 、 Monophosphoryl lipid A (synthetic) 、 GLA (ADJUVANT) AMMONIUM 、 LAPRETOLIMOD AMMONIUM 、 CS-0107253 、 HY-130320 、 HEXAACYL MONOPHOSPHORYL LIPID A AMMONIUM SALT 、磷酸化六酰基二糖 、 吡喃葡糖苷脂类 A

产品性质

CAS编号：1246298-63-4

分子式：C96H184N3O22P

分子量：1763.47

PubChem编号：134687617

别名：磷酸化六酰基二糖 | 吡喃葡糖苷脂类 A

英文别名：GLA | GLUCOPYRANOSYL LIPID A AMMONIUM | GLA-SE | MONOPHOSPHORYL LIPID A (SYNTHETIC) AMMONIUM | Monophosphoryl lipid A (synthetic) | GLA (ADJUVANT) AMMONIUM | LAPRETOLIMOD AMMONIUM | CS-0107253 | HY-130320 | HEXAACYL MONOPHOSPHORYL LIPID A AMMONIUM SALT |

规格或纯度：99%

英文名称：Monophosphoryl Lipid A (Synthetic)

生化机理：单磷酰脂质A(MPLA)是toll样受体(TLR4)的天然激动剂。它可用作免疫佐剂。单磷酰脂质A是安全的预防性药物，可用于免疫治疗。在疫苗中使用单磷酰脂质A可提高B细胞和T细胞介导免疫力

储存温度：-20°C储存

运输条件：超低温冰袋运输

产品介绍：通过在感染前产生病原体特异性免疫应答，接种疫苗被公认为预防感染的有效方法。通常，单独使用疫苗抗原进行免疫接种并不能够诱导稳健或持久的免疫反应——导致抵抗感染的保护性免疫失败。因此，需要佐剂增强免疫后的细胞或体液免疫应答。单磷酰脂质A(MPLA)可从细菌类脂A中提取或通过化学法合成； PHAD单磷酰脂质A®已用于 作为钴卟啉-磷脂(Co-PoP)脂质体组分，用于使用gp41包膜蛋白的近膜端外部区(MPER)免疫小鼠； 与双十八烷基二甲基溴化铵(DDA)共同作为佐剂，用于基于沙眼衣原体重组膜蛋白的多亚单位疫苗； 用作呼吸道合胞病毒(RSV)融合(F)蛋白FI-RSV疫苗的toll样受体4(TLR4)激动剂佐剂 By generating a pathogen-specific immune response before infection, vaccination is recognized as an effective way to prevent infection. Typically, immunization with vaccine antigens alone does not induce a robust or durable immune response - leading to a failure of protective immunity against infection. Therefore, adjuvants are needed to enhance the cellular or humoral immune response after immunization. Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.MPLA has been used• as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein• as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine• as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine

IUPAC Name：azanium;[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R,6S)-3,6-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]-4-[(3R)-3-hydroxytetradecanoyl]oxyoxan-2-yl]methoxy]-2-(hydroxymethyl)-5-[[(3R)-3-tetradecanoyloxytetradecanoyl]amino]-4-[(3R)-3-tetradecanoyloxytetradecanoyl]oxyoxan-3-yl] hydrogen phosphate

INCHI：InChI=1S/C96H181N2O22P.H3N/c1-7-13-19-25-31-37-39-45-51-57-63-69-85(104)114-79(67-61-55-49-43-35-29-23-17-11-5)73-84(103)98-90-94(119-88(107)74-80(68-62-56-50-44-36-30-24-18-12-6)115-86(105)70-64-58-52-46-40-38-32-26-20-14-8-2)92(120-121(110,111)112)81(75-99)117-96(90)113-76-82-91(108)93(118-87(106)72-78(101)66-60-54-48-42-34-28-22-16-10-4)89(95(109)116-82)97-83(102)71-77(100)65-59-53-47-41-33-27-21-15-9-3;/h77-82,89-96,99-101,108-109H,7-76H2,1-6H3,(H,97,102)(H,98,103)(H2,110,111,112);1H3/t77-,78-,79-,80-,81-,82-,89-,90-,91-,92-,93-,94-,95+,96-;/m1./s1

InChi Key：UPAZUDUZKTYFBG-HNPUZVNISA-N

Canonical SMILES：CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)NC1C(C(C(OC1OCC2C(C(C(C(O2)O)NC(=O)CC(CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O)CO)OP(=O)(O)[O-])OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC.[NH4+]

Isomeric SMILES：CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O)NC(=O)C[C@@H](CCCCCCCCCCC)O)OC(=O)C[C@@H](CCCCCCCCCCC)O)O)CO)OP(=O)(O)[O-])OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC.[NH4+]

PubChem CID：134687617

象形图：

信号词：Warning

危险声明：H335 May cause respiratory irritationH373 Causes damage to organs through prolonged or repeated exposureH371 May cause damage to organs

预防措施声明：P261,P405,P501,P264,P260,P271,P270,P304+P340,P403+P233,P308+P316,P319

产品包装